<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                            March 17, 2025

Harout Semerjian
President and Chief Executive Officer
GlycoMimetics, Inc.
P.O. Box 65
Monrovia, MD 21770

       Re: GlycoMimetics, Inc.
           Registration Statement on Form S-4
           Filed February 18, 2025
           File No. 333-285035
Dear Harout Semerjian:

       We have reviewed your registration statement and have the following
comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-4
Cover Page

1.     As required by Item 501(b)(2) of Regulation S-K, as referenced in Item 1
of Form S-
       4, please disclose the amount of securities being offered.
2.     You state that your shares are currently listed on Nasdaq and that it is
a waivable
       condition to the consummation of the merger that the combined company is
approved
       for listing on Nasdaq. Given this condition, please clarify here that
you are currently
       not in compliance with the Nasdaq listing requirements. In addition,
given that this
       condition is waivable, please revise your disclosure to indicate whether
recirculation
       or re-solicitation of stockholders will occur prior to the closing if
the listing
       application is not approved but the condition is waived. If stockholders
will not have
       certainty regarding the listing of the combined company's shares at the
time they are
       asked to vote, please clarify this fact here and elsewhere in the proxy
       statement/prospectus as appropriate. Please also provide risk factor
disclosure that
 March 17, 2025
Page 2

       addresses the potential consequences of the parties waiving the
condition and the
       closing occurring without the Nasdaq listing, including but not limited
to the liquidity
       implications thereof.
Questions and Answers about the Merger
What is the Merger?, page iii

3.     Please disclose the number of shares of common stock you expect to
issue, or
       otherwise reserve for issuance, in connection with the merger. In your
disclosure,
       separately state the number of shares you expect to underlie shares of
the Series A
       Preferred Stock and pre-funded warrants to be issued upon consummation
of the
       merger.
What proposals will be voted on at the GlycoMimetics Special Meeting in
connection with
the Merger?, page v

4.     You state that Proposal No. 2 must be approved to have an adequate
number of
       authorized but unissued shares of common stock to complete the merger.
Please
       disclose the number of additional authorized shares you expect to need
to complete
       the merger and disclose the number of authorized shares that will be
available for
       issuance after factoring in the number of shares to be issued in
connection with the
       merger if this proposal is approved.
What proposals are to be voted on at the GlycoMimetics Special Meeting, other
than the
Nasdaq Issuance Proposal..., page vi

5.     We note that Proposal No. 4 is a proposal to elect directors. Given the
inclusion of this
       proposal, please tell us why you have not also included an advisory
proposal in the
       proxy statement/prospectus for stockholders to approve executive
compensation
       pursuant to Exchange Act Rule 14a-21(a). Alternatively, revise the proxy
       statement/prospectus to include such proposal.
If my GlycoMimetics shares are held in "street name" by my broker..., page ix

6.     You state that if a beneficial owner does not instruct such owner's
broker, bank or
       other agent how to vote such owner's shares, the broker, bank or other
agent may still
       be able to vote such shares in its discretion. Please disclose for which
of the proposals
       brokers, banks and other agents will be able to vote shares in the
absence of
       instructions from the respective beneficial owner.
Prospectus Summary
The Companies
Crescent, page 1

7.     Revise your summary of Crescent to disclose the following:
           that Crescent was founded in September 2024 and launched to research
and
          develop antibody and ADC candidates from Paragon Therapeutics, Inc.,
an
          antibody discovery engine founded by Fairmount Funds Management LLC;
           that Crescent does not yet have any product candidates but, instead,
has
          unexercised options under the Paragon Option Agreements to license
the CR-001
 March 17, 2025
Page 3

           and CR-002 product candidates from Paragon;
             identify Paragon, Fairmount and Parascent as related parties;
             disclose, if true, that Crescent does not currently have any
in-house development
           capabilities and that Paragon has launched other companies with
intellectual
           property or assets that Paragon has developed in-house;
             clarify if Crescent would be entitled to any improvements on
CR-001 and CR-002
           that Paragon develops, or if Paragon could grant the rights to any
such
           improvements, or to any new and competing technologies, to other
companies
           against which Crescent would compete, and include risk factor
disclosure as
           appropriate; and
             include a cross reference to a more fulsome discussion of
Crescent's relationship,
           and the nature of these arrangements, with Paragon.
8.     Given that Crescent was recently formed in September 2024 and that it
has not yet
       exercised any options under the Paragon Option Agreements, please revise
your
       disclosure here and throughout the proxy statement/prospectus as
appropriate to
       clarify the current state of Crescent's business. For example, if
Crescent is not yet
       "developing" product candidates and has not yet exercised its option for
CR-001, you
       might clarify that Crescent "intends to develop" or "is collaborating
with Paragon to
       develop" or "to advance" product candidates and that it "expects" CR-001
to be its
       initial product candidate, subject to Crescent's exercise of the option
and entry into the
       respective license agreement.
9.     We note your statement that Crescent believes the emerging data from the
clinical
       development of ivonescimab allows for the acceleration of the
development of CR-
       001. Please provide a more detailed explanation of why you believe the
development
       of ivonescimab will allow you to accelerate the development of CR-001, a
new
       molecular entity. We further note your statement that Crescent plans to
       "systematically" seek regulatory approvals for CR-001 to treat multiple
solid tumor
       indications. Please clarify what you mean by "systematically" seeking
regulatory
       approvals, and balance these statements with the fact that Crescent has
not yet begun
       clinical development of CR-001, that there is no guarantee Crescent will
be able to
       accelerate development of CR-001 and that it will be several years
before Crescent
       will be able to commercialize CR-001 if it is able to successfully
complete clinical
       trials and obtain the requisite regulatory approvals.
10.    To the extent known, please disclose if and when Crescent expects to
exercise its
       options for CR-001 and CR-002. In addition, briefly describe the
influence, if any,
       that Fairmount and Paragon may have over any decision to exercise the
options and in
       negotiating the terms of the respective licensing agreements. In this
regard, in
       addition to the relationship between Crescent, Paragon, Fairmount and
Parascent, we
       note your Chief Executive Officer's affiliation with Fairmount and the
rights of
       preferred stockholders to elect directors.
Risk Factors, page 16

11.    We note from Section 11.1 of the Merger Agreement that the
representations and
       warranties of the parties contained in the Merger Agreement do not
survive the
 March 17, 2025
Page 4

      closing and that there are no indemnification rights. Please include
appropriate risk
      factor disclosure.
The Special Meeting in Lieu of Annual Meeting of GlycoMimetics Stockholders
Solicitation of Proxies, page 98

12.   We note that you have retained Innisfree M&A Incorporated as your proxy
solicitor.
      Please disclose the material features of any contract or arrangement for
such
      solicitation and the cost or anticipated cost thereof. Refer to Item
4(a)(3) of Schedule
      14A.
Anticipated Accounting Treatment, page 130

13.   You disclose that you expect to account for the merger as a reverse
      recapitalization. Revise this section as well as your disclosures on
pages 13 and 290 to
      address the following:
          Disclose the extent to which you have determined that, immediately
before the
          merger, GlycoMimetics will have no or nominal operations.
          Disclose the extent to which you have determined that, immediately
before the
          merger, GlycoMimetics will have no or nominal assets, assets
consisting solely of
          cash and cash equivalents, or assets consisting of any amount of cash
and cash
          equivalents and nominal other assets.
Agreements Related to the Merger
Lock-Up Agreements, page 151

14.   You state that the Crescent stockholders who have executed lock-up
agreements as of
      February 7, 2025 owned, in the aggregate, approximately 98.5% of the
shares of
      Crescent's outstanding capital stock. Please also disclose the percentage
of shares you
      expect to be subject to the lock-up agreements on a fully diluted basis
immediately
      following consummation of the merger.
Subscription Agreement, page 151

15.   To the extent not already described in this section, please revise your
disclosure to
      briefly describe the material terms of the pre-funded warrants to be
issued in
      connection with the merger transactions, including, for example, the
exercise price
      and duration of the warrants.
Consulting Agreements and Offer Letters, page 172

16.   Please disclose the term of Crescent's consulting agreement and offer
letter with Dr.
      Violin and Mr. Doughty, respectively. In addition, given Dr. Violin's
affiliation with
      Fairmount and the fact that Dr. Violin does not appear to be an employee
of Crescent,
      please briefly describe any potential conflicts of interest or other
risks that may arise
      in connection with Dr. Violin's consulting arrangement with Crescent, and
to the
      extent material, include appropriate risk factor disclosure regarding the
same.
 March 17, 2025
Page 5
Matters Being Submitted to a Vote of GlycoMimetics Stockholders
Proposal No. 2 - The Authorized Share Increase Proposal
Background and Reasons for the GlycoMimetics Share Increase Amendment, page 177

17.    In the fourth paragraph, you disclose the number of shares outstanding
and reserved
       for issuance as of the Record Date, as well as the number of shares that
will remain
       available for issuance upon effectiveness of the Share Increase
Amendment. Please
       also provide corresponding disclosures regarding the number of shares
expected to be
       outstanding, reserved for issuance and available for issuance following
consummation
       of the merger.
Possible Effects of the GlycoMimetics Share Increase Amendment, page 178

18.    Please revise your disclosure in this section to also address any
potential anti-takeover
       effects the Share Increase Amendment may have if effected.
Proposal No. 3 - The Reverse Stock Split Proposal
Requirements for Listing on Nasdaq, page 181

19.    Please revise your disclosure in this section to clarify that you are
currently not in
       compliance with Nasdaq's minimum bid price requirement and to disclose
the
       deadline by which you are required to regain compliance to maintain the
listing of
       your common stock on Nasdaq. In addition, clarify here that the
condition to closing
       of the merger that the shares of common stock to be issued in the merger
be approved
       for listing on Nasdaq is a waivable condition.
Proposal No. 5 - The Auditor Ratification Proposal, page 188

20.    Please include the disclosures required by Item 9(e) of Schedule 14A.
Crescent's Business, page 216

21.    We note your discussions regarding third-party product candidates,
including
       ivonescimab, as well as certain statements regarding the safety and
efficacy of
       ivonescimab (e.g., that ivonescimab "demonstrate[d] improved clinical
efficacy
       compared to pembrolizumab (Keytruda) in a head-to-head Phase 3 clinical
trial"). We
       further note that Crescent intends to design a Phase 1 clinical trial of
CR-001 based on
       the clinical profile of ivonescimab. Please revise your disclosures to
address the
       following:
           Clarify that the clinical trials described were third-party trials
and, to the extent
           known, briefly describe the clinical trial protocols, including the
number of
           participants, primary and secondary endpoints and the objective
results from the
           clinical trials.
           Remove statements that may imply that a product candidate is safe or
effective as
           such determinations are solely within the authority of the FDA and
corresponding
           regulatory authorities.
           Clearly state that neither Crescent nor Paragon has conducted any
clinical trials
           with CR-001 and that there is no guarantee that clinical trials with
CR-001 will
           have similar results as compared to clinical trials with other
products and product
           candidates.
 March 17, 2025
Page 6

22.    We note your disclosure that "[b]inding of VEGF, an angiogenic growth
factor that
       stimulates the growth of blood vessels and is overexpressed in many
tumors, to CR-
       001 leads to the formation of molecular complexes through polymerization
of CR-
       001" ... and that "[t]his increases its binding to PD-1 on immune cells
and is designed
       to lead to more potent antitumor activity." Please clarify if this
statement is based on
       the disclosure from page 221 that is related to the in vitro studies of
ivonescimab that
       you indicate were reported by Akeso Biopharma and Summit Therapeutics.
If so,
       please caution investors that pre-clinical or other studies of CR-001
may not show
       similar results.
Crescent's Pipeline, page 217

23.    Please revise the pipeline table to include a column for each of Phase
1, Phase 2 and
       Phase 3 clinical trials.
24.    We note the inclusion of CR-002 and CR-003 in Crescent's pipeline table.
Given the
       early stage of development and limited disclosure related to these
programs, please
       explain why they are sufficiently material to Crescent's business to
warrant inclusion
       in the pipeline table. If they are material, please expand your
disclosure to provide a
       more fulsome discussion of these programs, including a description of
development
       activities conducted. Alternatively, remove any programs that are not
currently
       material from the pipeline table.
The breakthrough potential of ivonescimab, an anti-PD-1/anti-VEGF bispecific
molecule,
page 219

25.    We note your disclosure that "[i]n a Phase 3 clinical trial in NSCLC,
ivonescimab
       demonstrated a statistically significant and clinically meaningful
improvement in PFS
       compared to pembrolizumab." Please clarify if this refers to the
HARMONi-2 trial
       described in the next paragraph, and disclose where such study was
conducted and
       where regulatory approval is being sought for ivonescimab as a result of
such trial.
The design of CR-001, page 222

26.    In the first paragraph, you state that Crescent has filed composition of
matter claims
       for the CR-001 sequence based in part on Crescent's proprietary scFv
engineering.
       Please reconcile this statement with your disclosure on page 228 that,
prior to entry
       into a License Agreement, Paragon is responsible for the prosecution,
defense,
       maintenance and enforcement of patents related to a Research Program.
In vitro activity, page 222

27.    Please provide the p-values for the results shown in the tables in this
section.
Clinical potential for CR-001, page 223

28.    You refer to the potential to establish CR-001 as a "first-in-class"
therapy. Given that
       ivonescimab is in Phase 3 clinicals trials, your early stage of
development and the
       length of the drug development process, such characterization appears to
be
       inapplicable or premature. Accordingly, please remove the statement or
otherwise
       advise.
 March 17, 2025
Page 7

Planned clinical development of CR-001, page 223

29.   Please disclose the regulatory jurisdictions where Crescent intends to
conduct its
      proposed Phase 1 clinical trial for CR-001.
Paragon Option Agreements, page 227

30.   We note your disclosure in the first full paragraph on page 229 that "as
part of the
      Paragon Option Agreements, on each of December 31, 2025 and December 31,
2026,
      Crescent will grant Parascent warrants to purchase a number of shares
equal to 1.00%
      of Crescent's outstanding capital stock as of the date of the grant on a
fully-diluted
      basis, with an exercise price equal to the fair market value of the
underlying shares of
      Crescent common stock on each respective grant date." We also note that
pursuant to
      Section 5.8 of the Antibody Paragon Option Agreement that, if Crescent
undergoes an
      initial public offering or a reverse merger transaction, the rights and
obligations of
      Section 5.8 shall continue and Parascent shall be entitled to warrants
from the ultimate
      public company parent to purchase a number of shares of such parent equal
to 1.00%
      of the outstanding shares of the parent as of the date of the grant, on a
fully-diluted
      basis (assuming the exercise or conversion of any convertible non-voting
preferred
      stock, stock options, pre-funded warrants or similar instruments), as
applicable. Please
      clarify if the transactions contemplated by the Merger Agreement will
constitute a
      reverse merger for purposes of Section 5.8 of the Antibody Paragon Option
      Agreement and, if so, if the reverse merger warrants would be in addition
to the
      annual warrant grants.
31.   You state on page 229 that "As of the date of this proxy
statement/prospectus,
      Crescent has paid Paragon (i) $6.2 million under the Antibody Paragon
Option
      Agreement for development costs related to PD-1 and VEGF incurred by
Paragon
      through the effective date of the agreement, including pre-development
costs, and
      (ii) $0.8 million under the ADC Paragon Option Agreement for development
costs
      related to the undisclosed CR-002 target incurred by Paragon through the
effective
      date of the agreement." Please reconcile the $6.2 million with the
amounts disclosed
      in the preceding paragraphs, as applicable, and to the $9.9 million of
research and
      development expense through December 31, 2024, as described on pages
264-265.
32.   Please revise your disclosure hereunder to clarify the extent to which
Paragon had any
      historical assets, liabilities or cash flows associated with CR-001 or
any other product
      in Crescent's pipeline and, if so, provide such quantification. Revise to
disclose the
      extent to which Paragon's cash flows related to these product candidates
were
      operating cash flows.
 March 17, 2025
Page 8
Intellectual Property, page 229

33.    We note your disclosure that Paragon has filed provisional patent
applications relating
       to CR-001 and CR-002. Please disclose the jurisdictions where such
filings were
       made.
Crescent's Management's Discussion and Analysis of Financial Condition and
Results of
Operations
Stock-Based Compensation, page 271

34.    Please address the following regarding the stock options and restricted
stock units
       granted by Crescent:
           Revise to provide a tabular presentation or revise your table on
page 173 to
           provide the grant date, number of options or restricted stock units
granted,
           exercise price, valuation of common stock used, compensation expense
           recognized for all options and restricted stock units granted.
           Tell us and revise your disclosure to explain how the valuation used
compares to
           the exchange ratio of the merger.
           Tell us and revise your disclosure to address how the valuation
process considered
           the common control nature of the relationship between Crescent and
Paragon at
           the time of the grant. Further, explain how the valuation considered
eventual
           conclusion of the overall plan of licensing of CR-001, CR-002, and
CR-003
           between related parties.
Management Following the Merger
Executive Officers and Directors, page 274

35.    Please identify which directors are expected to be elected as the
"Preferred Directors"
       by the holders of the GlycoMimetics Series A Preferred Stock following
       consummation of the merger. We also note from Section 4.3.5 of the form
of
       Certificate of Designation of Preferences, Rights and Limitations of
Series A Non-
       Voting Convertible Preferred Stock included as Annex F that each
Preferred Director
       shall be entitled to three votes on each matter presented to the board
of directors.
       Please revise to describe those provisions and to disclose if those
provisions will
       effectively give the Preferred Directors control over decisions to be
made by the board
       following the merger and include appropriate risk factor disclosure.
Description of GlycoMimetics Capital Stock
Description of Preferred Stock, page 295

36.    We note the disclosure that at any time that at least 30% of the
originally issued Series
       A Preferred Stock remains issued and outstanding, the affirmative vote
of the holders
       of a majority of the then outstanding shares of Series A Preferred Stock
shall be
       required to consummate a fundamental transaction or merger. Please
include risk
       factor disclosure that addresses these voting provisions and that make
clear that these
       provisions could prevent potential changes of control that could offer a
premium over
       the market value of the Combined Company to the common stockholders.
 March 17, 2025
Page 9
Choice of Forum, page 297

37.    Similar to your risk factor disclosure on page 88, please revise your
disclosure in this
       section to clarify that the exclusive forum provision is not intended to
apply to causes
       of action arising under the Securities Act and the Exchange Act.
Crescent Biopharma, Inc.'s Financial Statements
Note 14, Subsequent Events, page F-44

38.    We note your disclosure on page 226 that Crescent's rights to acquire
the rights to CR-
       001 and CR-002 remain unexercised. We also note your disclosure on page
216 that
       Crescent expects to amend the ADC Paragon Option Agreement to include
CR-
       003. Revise this note as well as your MD&A to address the following:
           Revise to concisely provide the current status and expected status
as of
          effectiveness for the licenses of CR-001, CR-002 and CR-003. Confirm
that you
          will provide updates to such disclosures here in each pre-effective
amendment.
           As part of your disclosures, provide the amounts paid versus amounts
payable for
          each product candidate.
           Revise to clarify the extent to which the research performed to date
was
          performed by Paragon versus Crescent for each product candidate,
identifying
          how the research is allocated between each company for each product
candidate.
General

39.    Please tell us if you intend to register the exchange of the
GlycoMimetics preferred
       stock for the Crescent preferred stock, and the GlycoMimetics pre-funded
warrants for
       the Crescent pre-funded warrants, or are relying on private placement
exemptions.

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Jenn Do at 202-551-3743 or Kevin Vaughn at 202-551-3494
if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jessica Dickerson at 202-551-8013 or Tim Buchmiller at 202-551-3635
with any
other questions.



                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Life
Sciences
cc:   Kostian Ciko, Esq.
</TEXT>
</DOCUMENT>
